These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 9515574)

  • 1. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.
    Kruczynski A; Barret JM; Etiévant C; Colpaert F; Fahy J; Hill BT
    Biochem Pharmacol; 1998 Mar; 55(5):635-48. PubMed ID: 9515574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity.
    Lobert S; Ingram JW; Hill BT; Correia JJ
    Mol Pharmacol; 1998 May; 53(5):908-15. PubMed ID: 9584218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine.
    Ngan VK; Bellman K; Hill BT; Wilson L; Jordan MA
    Mol Pharmacol; 2001 Jul; 60(1):225-32. PubMed ID: 11408618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BM6, a new semi-synthetic vinca alkaloid, exhibits its potent in vivo anti-tumor activities via its high binding affinity for tubulin and improved pharmacokinetic profiles.
    Li W; Shao Y; Hu L; Zhang X; Chen Y; Tong L; Li C; Shen X; Ding J
    Cancer Biol Ther; 2007 May; 6(5):787-94. PubMed ID: 17387272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules.
    Ngan VK; Bellman K; Panda D; Hill BT; Jordan MA; Wilson L
    Cancer Res; 2000 Sep; 60(18):5045-51. PubMed ID: 11016627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine.
    Lobert S; Vulevic B; Correia JJ
    Biochemistry; 1996 May; 35(21):6806-14. PubMed ID: 8639632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vinflunine, a second generation novel Vinca Alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers.
    Hill BT
    Curr Pharm Des; 2001 Sep; 7(13):1199-212. PubMed ID: 11472262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinflunine, a new vinca alkaloid: cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells.
    Jean-Decoster C; Brichese L; Barret JM; Tollon Y; Kruczynski A; Hill BT; Wright M
    Anticancer Drugs; 1999 Jul; 10(6):537-43. PubMed ID: 10885901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics.
    Okouneva T; Hill BT; Wilson L; Jordan MA
    Mol Cancer Ther; 2003 May; 2(5):427-36. PubMed ID: 12748304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties.
    Kruczynski A; Hill BT
    Crit Rev Oncol Hematol; 2001 Nov; 40(2):159-73. PubMed ID: 11682323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid.
    Kruczynski A; Colpaert F; Tarayre JP; Mouillard P; Fahy J; Hill BT
    Cancer Chemother Pharmacol; 1998; 41(6):437-47. PubMed ID: 9554586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Energetics of vinca alkaloid interactions with tubulin isotypes: implications for drug efficacy and toxicity.
    Lobert S; Frankfurter A; Correia JJ
    Cell Motil Cytoskeleton; 1998; 39(2):107-21. PubMed ID: 9484953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vinflunine, a novel microtubule inhibitor, suppresses calmodulin interaction with the microtubule-associated protein STOP.
    Makarov AA; Tsvetkov PO; Villard C; Esquieu D; Pourroy B; Fahy J; Braguer D; Peyrot V; Lafitte D
    Biochemistry; 2007 Dec; 46(51):14899-906. PubMed ID: 18052208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain.
    Bai R; Pettit GR; Hamel E
    Biochem Pharmacol; 1990 Jun; 39(12):1941-9. PubMed ID: 2353935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data.
    Bai RL; Paull KD; Herald CL; Malspeis L; Pettit GR; Hamel E
    J Biol Chem; 1991 Aug; 266(24):15882-9. PubMed ID: 1874739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vinca alkaloid-induced tubulin spiral formation correlates with cytotoxicity in the leukemic L1210 cell line.
    Lobert S; Fahy J; Hill BT; Duflos A; Etievant C; Correia JJ
    Biochemistry; 2000 Oct; 39(39):12053-62. PubMed ID: 11009620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential binding to the alpha/beta-tubulin dimer of vinorelbine and vinflunine revealed by nuclear magnetic resonance analyses.
    Fabre C; Czaplicki J; Wright M; Hill B; Barret JM; Fahy J; Milon A
    Biochem Pharmacol; 2002 Aug; 64(4):733-40. PubMed ID: 12167492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain.
    Bai R; Taylor GF; Cichacz ZA; Herald CL; Kepler JA; Pettit GR; Hamel E
    Biochemistry; 1995 Aug; 34(30):9714-21. PubMed ID: 7626642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Biological Activity of the Novel Vinca Alkaloids 4-chlorochablastine and 4-chlorochacristine.
    Montag G; Stopper H; Ngo QA; Hintzsche H
    Curr Cancer Drug Targets; 2019; 19(3):222-230. PubMed ID: 29714145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Murine leukemia P388 vinorelbine-resistant cell lines are sensitive to vinflunine.
    Aggarwal A; Kruczynski A; Frankfurter A; Correia JJ; Lobert S
    Invest New Drugs; 2008 Aug; 26(4):319-30. PubMed ID: 18071633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.